[10-Q] BIO-key International, Inc. Quarterly Earnings Report
BIO-key International, Inc. (BKYI) reported mixed quarterly results with revenue growth but continued losses and a going-concern qualification. For the three months ended June 30, 2025, total revenue was $1,696,907, up from $1,141,286 a year earlier, driven by higher hardware sales and modest license and services growth. Gross profit improved to $1,232,727. The company recorded a net loss of $1,167,396 for the quarter (basic and diluted loss per share $0.20) and a six-month net loss of $1,903,941.
Liquidity changed materially: cash and cash equivalents rose to $2,275,344 from $437,604 at year-end, largely from warrant exercises that generated gross proceeds of approximately $3.8 million and $3,493,505 of net financing cash. Working capital was about $503,000. Management discloses substantial doubt about the company's ability to continue as a going concern without additional financing. Major customer concentration remains (two customers represented 47% of quarterly revenue) and inventory includes a large reserve against finished goods related to delayed projects.
BIO-key International, Inc. (BKYI) ha riportato risultati trimestrali contrastanti: ricavi in crescita ma perdite persistenti e un'incertezza sulla capacit脿 di proseguire l'attivit脿. Per i tre mesi chiusi il 30 giugno 2025, i ricavi totali sono stati $1,696,907, in aumento rispetto a $1,141,286 dell'anno precedente, trainati da maggiori vendite di hardware e da una modesta crescita di licenze e servizi. Il margine lordo 猫 migliorato a $1,232,727. La societ脿 ha registrato una perdita netta di $1,167,396 per il trimestre (perdita base e diluita per azione $0.20) e una perdita netta sui sei mesi di $1,903,941.
La situazione della liquidit脿 猫 cambiata in modo significativo: la cassa e gli equivalenti di cassa sono saliti a $2,275,344 da $437,604 a fine esercizio, principalmente grazie all'esercizio di warrant che ha generato proventi lordi per circa $3.8 milioni e $3,493,505 di flussi finanziari netti da finanziamento. Il capitale circolante era circa $503,000. La direzione dichiara dubbi sostanziali sulla capacit脿 della societ脿 di continuare come azienda in funzionamento senza finanziamenti aggiuntivi. Permane una forte concentrazione clienti (due clienti hanno rappresentato il 47% dei ricavi trimestrali) e le scorte includono una consistente riserva su prodotti finiti legata a progetti ritardati.
BIO-key International, Inc. (BKYI) present贸 resultados trimestrales mixtos: crecimiento de ingresos pero p茅rdidas continuadas y una salvedad sobre la capacidad de continuar como empresa en funcionamiento. Para los tres meses terminados el 30 de junio de 2025, los ingresos totales fueron $1,696,907, frente a $1,141,286 del a帽o anterior, impulsados por mayores ventas de hardware y un modesto crecimiento en licencias y servicios. La utilidad bruta mejor贸 a $1,232,727. La compa帽铆a registr贸 una p茅rdida neta de $1,167,396 en el trimestre (p茅rdida b谩sica y diluida por acci贸n $0.20) y una p茅rdida neta de seis meses de $1,903,941.
La liquidez cambi贸 de forma material: el efectivo y equivalentes aumentaron a $2,275,344 desde $437,604 a fin de a帽o, en gran parte por el ejercicio de warrants que gener贸 ingresos brutos de aproximadamente $3.8 millones y $3,493,505 de efectivo neto por financiamiento. El capital de trabajo fue de alrededor de $503,000. La gerencia manifiesta dudas sustanciales sobre la capacidad de la compa帽铆a para continuar como empresa en funcionamiento sin financiamiento adicional. Permanece una alta concentraci贸n de clientes (dos clientes representaron el 47% de los ingresos trimestrales) y el inventario incluye una gran provisi贸n contra productos terminados relacionada con proyectos retrasados.
BIO-key International, Inc. (BKYI)電� 毵れ稖 歃濌皜鞐愲弰 攵堦惮頃橁碃 靻愳嫟鞚� 歆�靻嶋悩瓿� 瓿勳啀旮办梾(going concern)鞐� 雽�頃� 鞙犽炒臧� 鞛堧姅 順检灛霅� 攵勱赴 鞁れ爜鞚� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 30鞚茧 雭濍倶電� 3臧滌洈 霃欖晥 齑濍Г於滌潃 $1,696,907搿� 鞝勲厔鞚� $1,141,286氤措嫟 歃濌皜頄堨溂氅�, 鞚措姅 頃橂摐鞗柎 韺愲Г 歃濌皜鞕� 霛检澊靹犾姢 氚� 靹滊箘鞀れ潣 靻岉彮 靹膘灔鞐� 旮办澑頃╇媹雼�. 毵れ稖齑濎澊鞚奠潃 $1,232,727搿� 臧滌劆霅橃棃鞀惦媹雼�. 須岇偓電� 攵勱赴 靾滌啇鞁� $1,167,396(欤茧嫻 旮半掣 氚� 頋劃 靻愳嫟 $0.20)瓿� 6臧滌洈 雸勱硠 靾滌啇鞁� $1,903,941鞚� 旮半頄堨姷雼堧嫟.
鞙犽彊靹膘潃 韥矊 氤�霃欗枅鞀惦媹雼�: 順勱笀 氚� 順勱笀靹膘瀽靷办潃 鞐半 $437,604鞐愳劀 $2,275,344搿� 歃濌皜頄堨溂氅�, 鞚措姅 欤茧 鞗岆煱韸� 頄夓偓搿� 鞎� $3.8氚彪鞚� 齑濎垬鞚店臣 $3,493,505鞚� 靾滌灛氍错槃旮堨澊 氚滌儩頃� 雿� 霐半ジ 瓴冹瀰雼堧嫟. 鞖挫爠鞛愲掣鞚� 鞎� $503,000鞚挫棃鞀惦媹雼�. 瓴届榿歆勳潃 於旉皜 鞛愱笀 臁半嫭 鞐嗢澊電� 須岇偓臧� 瓿勳啀旮办梾鞙茧 臁挫啀頃� 靾� 鞛堨潉歆�鞐� 雽�頃� 欷戨寑頃� 鞚橂鞚� 鞝滉赴頃橁碃 鞛堨姷雼堧嫟. 欤检殧 瓿犼皾 歆戩霃勲姅 鞐爠頌� 雴掛溂氅�(霊� 瓿犼皾鞚� 攵勱赴 毵れ稖鞚� 47%毳� 彀), 鞛碃鞐愲姅 歆�鞐半悳 頂勲鞝濏姼鞕� 甏�霠悳 鞕勳牅頀堨棎 雽�頃� 韥� 於╇嫻旮堨澊 韽暔霅橃柎 鞛堨姷雼堧嫟.
BIO-key International, Inc. (BKYI) a publi茅 des r茅sultats trimestriels mitig茅s : croissance du chiffre d'affaires mais pertes persistantes et r茅serve sur la continuit茅 d'exploitation. Pour les trois mois clos le 30 juin 2025, le chiffre d'affaires total s'est 茅lev茅 脿 $1,696,907, contre $1,141,286 un an plus t么t, tir茅 par des ventes de mat茅riel plus 茅lev茅es et une l茅g猫re progression des licences et services. La marge brute s'est am茅lior茅e 脿 $1,232,727. La soci茅t茅 a enregistr茅 une perte nette de $1,167,396 pour le trimestre (perte de base et dilu茅e par action $0.20) et une perte nette sur six mois de $1,903,941.
La liquidit茅 a 茅volu茅 de mani猫re significative : les liquidit茅s et 茅quivalents de tr茅sorerie sont pass茅s de $437,604 脿 la cl么ture de l'exercice 脿 $2,275,344, principalement en raison de l'exercice de warrants ayant g茅n茅r茅 des produits bruts d'environ $3.8 millions et $3,493,505 de flux de tr茅sorerie nets li茅s au financement. Le fonds de roulement 茅tait d'environ $503,000. La direction exprime un doute substantiel sur la capacit茅 de la soci茅t茅 脿 poursuivre son activit茅 sans financement suppl茅mentaire. Une forte concentration client demeure (deux clients ont repr茅sent茅 47% du chiffre d'affaires trimestriel) et les stocks incluent une importante provision sur produits finis li茅e 脿 des projets retard茅s.
BIO-key International, Inc. (BKYI) meldete gemischte Quartalszahlen: Umsatzwachstum, aber weiterhin Verluste und ein Hinweis auf Zweifel an der Fortf眉hrungsf盲higkeit. F眉r die drei Monate zum 30. Juni 2025 lagen die Gesamterl枚se bei $1,696,907 gegen眉ber $1,141,286 im Vorjahr, getrieben von h枚heren Hardwareverk盲ufen und einem moderaten Wachstum bei Lizenzen und Dienstleistungen. Der Bruttogewinn verbesserte sich auf $1,232,727. Das Unternehmen verzeichnete einen Quartalsnettverlust von $1,167,396 (Grund- und verw盲sserter Verlust je Aktie $0.20) und einen Sechsmonatsverlust von $1,903,941.
Die Liquidit盲tslage 盲nderte sich deutlich: Zahlungsmittel und Zahlungsmittel盲quivalente stiegen von $437,604 zum Jahresende auf $2,275,344, haupts盲chlich durch die Aus眉bung von Warrants, die Bruttoerl枚se von etwa $3.8 Mio. und $3,493,505 an Nettofinanzierungszufluss erzeugten. Das Working Capital betrug etwa $503,000. Das Management 盲u脽ert erhebliche Zweifel an der Fortf眉hrungsf盲higkeit des Unternehmens ohne zus盲tzliche Finanzierung. Eine hohe Kundenkonzentration bleibt bestehen (zwei Kunden machten 47% des Quartalsumsatzes aus) und das Inventar enth盲lt eine gro脽e R眉ckstellung f眉r fertige Erzeugnisse im Zusammenhang mit verz枚gerten Projekten.
- Cash position strengthened to $2,275,344 at June 30, 2025 from $437,604 at December 31, 2024, primarily from financing proceeds
- Successful warrant exercise financing generated approximately $3.8 million gross proceeds and $3,493,505 net cash from financing in the six months
- Quarterly revenue growth to $1,696,907 (up 49% year-over-year) driven by increased hardware sales and license ramp in EMEA
- Gross profit improvement to $1,232,727 for the quarter, reflecting higher-margin revenue composition
- Going concern disclosed: company states it does not have enough cash for twelve months and substantial doubt exists about continuation
- Persistent net losses: net loss of $1,167,396 for the quarter and $1,903,941 for six months ended June 30, 2025
- Customer concentration: two customers accounted for 47% of revenue in the quarter and two customers comprised 49% of receivables
- Large reserved inventory: finished goods of $3,761,329 with a $3,496,080 reserve, indicating potential recoverability issues
- Debt terms risk: 2024 Note includes high potential penalties, exit fees and redemption mechanics that could accelerate cash demands
Insights
TL;DR: Revenue rebound and a $3.8M financing improved cash, but recurring losses and customer concentration keep risk elevated.
The quarter shows operational momentum with revenues up 49% year-over-year to $1.70M and gross profit rising to $1.23M, reflecting strong hardware orders and modest license growth. Cash increased to $2.28M after warrant exercises that provided ~ $3.8M gross proceeds, improving near-term liquidity and reducing outstanding 2024 Note principal to approximately $338,400. However, the company continues to report substantial net losses ($1.17M quarter, $1.90M six months) and remains dependent on financing. Customer concentration (two customers = 47% of quarterly revenue) and a large reserved inventory position are sources of operational and cash-flow risk. Overall impact: mixed; improves runway but not yet durable profitability.
TL;DR: Material going-concern disclosure and concentrated receivables pose key near-term risks despite improved cash.
Management explicitly states it does not have sufficient cash for twelve months and that substantial doubt exists regarding continuation as a going concern. While financing from warrant exercises provided $3.8M gross and increased cash to $2.28M, the company needs roughly $812,000 monthly to operate and may require additional capital within twelve months. Two customers accounted for 47% of quarterly revenue and two customers made up 49% of accounts receivable, increasing counterparty and collection risk. The 2024 Note carries onerous exit fees and default penalties, and inventory includes $3.76M of finished goods with a $3.50M reserve, underscoring recoverability uncertainties. Impact rating reflects significant risk to continuity.
BIO-key International, Inc. (BKYI) ha riportato risultati trimestrali contrastanti: ricavi in crescita ma perdite persistenti e un'incertezza sulla capacit脿 di proseguire l'attivit脿. Per i tre mesi chiusi il 30 giugno 2025, i ricavi totali sono stati $1,696,907, in aumento rispetto a $1,141,286 dell'anno precedente, trainati da maggiori vendite di hardware e da una modesta crescita di licenze e servizi. Il margine lordo 猫 migliorato a $1,232,727. La societ脿 ha registrato una perdita netta di $1,167,396 per il trimestre (perdita base e diluita per azione $0.20) e una perdita netta sui sei mesi di $1,903,941.
La situazione della liquidit脿 猫 cambiata in modo significativo: la cassa e gli equivalenti di cassa sono saliti a $2,275,344 da $437,604 a fine esercizio, principalmente grazie all'esercizio di warrant che ha generato proventi lordi per circa $3.8 milioni e $3,493,505 di flussi finanziari netti da finanziamento. Il capitale circolante era circa $503,000. La direzione dichiara dubbi sostanziali sulla capacit脿 della societ脿 di continuare come azienda in funzionamento senza finanziamenti aggiuntivi. Permane una forte concentrazione clienti (due clienti hanno rappresentato il 47% dei ricavi trimestrali) e le scorte includono una consistente riserva su prodotti finiti legata a progetti ritardati.
BIO-key International, Inc. (BKYI) present贸 resultados trimestrales mixtos: crecimiento de ingresos pero p茅rdidas continuadas y una salvedad sobre la capacidad de continuar como empresa en funcionamiento. Para los tres meses terminados el 30 de junio de 2025, los ingresos totales fueron $1,696,907, frente a $1,141,286 del a帽o anterior, impulsados por mayores ventas de hardware y un modesto crecimiento en licencias y servicios. La utilidad bruta mejor贸 a $1,232,727. La compa帽铆a registr贸 una p茅rdida neta de $1,167,396 en el trimestre (p茅rdida b谩sica y diluida por acci贸n $0.20) y una p茅rdida neta de seis meses de $1,903,941.
La liquidez cambi贸 de forma material: el efectivo y equivalentes aumentaron a $2,275,344 desde $437,604 a fin de a帽o, en gran parte por el ejercicio de warrants que gener贸 ingresos brutos de aproximadamente $3.8 millones y $3,493,505 de efectivo neto por financiamiento. El capital de trabajo fue de alrededor de $503,000. La gerencia manifiesta dudas sustanciales sobre la capacidad de la compa帽铆a para continuar como empresa en funcionamiento sin financiamiento adicional. Permanece una alta concentraci贸n de clientes (dos clientes representaron el 47% de los ingresos trimestrales) y el inventario incluye una gran provisi贸n contra productos terminados relacionada con proyectos retrasados.
BIO-key International, Inc. (BKYI)電� 毵れ稖 歃濌皜鞐愲弰 攵堦惮頃橁碃 靻愳嫟鞚� 歆�靻嶋悩瓿� 瓿勳啀旮办梾(going concern)鞐� 雽�頃� 鞙犽炒臧� 鞛堧姅 順检灛霅� 攵勱赴 鞁れ爜鞚� 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 30鞚茧 雭濍倶電� 3臧滌洈 霃欖晥 齑濍Г於滌潃 $1,696,907搿� 鞝勲厔鞚� $1,141,286氤措嫟 歃濌皜頄堨溂氅�, 鞚措姅 頃橂摐鞗柎 韺愲Г 歃濌皜鞕� 霛检澊靹犾姢 氚� 靹滊箘鞀れ潣 靻岉彮 靹膘灔鞐� 旮办澑頃╇媹雼�. 毵れ稖齑濎澊鞚奠潃 $1,232,727搿� 臧滌劆霅橃棃鞀惦媹雼�. 須岇偓電� 攵勱赴 靾滌啇鞁� $1,167,396(欤茧嫻 旮半掣 氚� 頋劃 靻愳嫟 $0.20)瓿� 6臧滌洈 雸勱硠 靾滌啇鞁� $1,903,941鞚� 旮半頄堨姷雼堧嫟.
鞙犽彊靹膘潃 韥矊 氤�霃欗枅鞀惦媹雼�: 順勱笀 氚� 順勱笀靹膘瀽靷办潃 鞐半 $437,604鞐愳劀 $2,275,344搿� 歃濌皜頄堨溂氅�, 鞚措姅 欤茧 鞗岆煱韸� 頄夓偓搿� 鞎� $3.8氚彪鞚� 齑濎垬鞚店臣 $3,493,505鞚� 靾滌灛氍错槃旮堨澊 氚滌儩頃� 雿� 霐半ジ 瓴冹瀰雼堧嫟. 鞖挫爠鞛愲掣鞚� 鞎� $503,000鞚挫棃鞀惦媹雼�. 瓴届榿歆勳潃 於旉皜 鞛愱笀 臁半嫭 鞐嗢澊電� 須岇偓臧� 瓿勳啀旮办梾鞙茧 臁挫啀頃� 靾� 鞛堨潉歆�鞐� 雽�頃� 欷戨寑頃� 鞚橂鞚� 鞝滉赴頃橁碃 鞛堨姷雼堧嫟. 欤检殧 瓿犼皾 歆戩霃勲姅 鞐爠頌� 雴掛溂氅�(霊� 瓿犼皾鞚� 攵勱赴 毵れ稖鞚� 47%毳� 彀), 鞛碃鞐愲姅 歆�鞐半悳 頂勲鞝濏姼鞕� 甏�霠悳 鞕勳牅頀堨棎 雽�頃� 韥� 於╇嫻旮堨澊 韽暔霅橃柎 鞛堨姷雼堧嫟.
BIO-key International, Inc. (BKYI) a publi茅 des r茅sultats trimestriels mitig茅s : croissance du chiffre d'affaires mais pertes persistantes et r茅serve sur la continuit茅 d'exploitation. Pour les trois mois clos le 30 juin 2025, le chiffre d'affaires total s'est 茅lev茅 脿 $1,696,907, contre $1,141,286 un an plus t么t, tir茅 par des ventes de mat茅riel plus 茅lev茅es et une l茅g猫re progression des licences et services. La marge brute s'est am茅lior茅e 脿 $1,232,727. La soci茅t茅 a enregistr茅 une perte nette de $1,167,396 pour le trimestre (perte de base et dilu茅e par action $0.20) et une perte nette sur six mois de $1,903,941.
La liquidit茅 a 茅volu茅 de mani猫re significative : les liquidit茅s et 茅quivalents de tr茅sorerie sont pass茅s de $437,604 脿 la cl么ture de l'exercice 脿 $2,275,344, principalement en raison de l'exercice de warrants ayant g茅n茅r茅 des produits bruts d'environ $3.8 millions et $3,493,505 de flux de tr茅sorerie nets li茅s au financement. Le fonds de roulement 茅tait d'environ $503,000. La direction exprime un doute substantiel sur la capacit茅 de la soci茅t茅 脿 poursuivre son activit茅 sans financement suppl茅mentaire. Une forte concentration client demeure (deux clients ont repr茅sent茅 47% du chiffre d'affaires trimestriel) et les stocks incluent une importante provision sur produits finis li茅e 脿 des projets retard茅s.
BIO-key International, Inc. (BKYI) meldete gemischte Quartalszahlen: Umsatzwachstum, aber weiterhin Verluste und ein Hinweis auf Zweifel an der Fortf眉hrungsf盲higkeit. F眉r die drei Monate zum 30. Juni 2025 lagen die Gesamterl枚se bei $1,696,907 gegen眉ber $1,141,286 im Vorjahr, getrieben von h枚heren Hardwareverk盲ufen und einem moderaten Wachstum bei Lizenzen und Dienstleistungen. Der Bruttogewinn verbesserte sich auf $1,232,727. Das Unternehmen verzeichnete einen Quartalsnettverlust von $1,167,396 (Grund- und verw盲sserter Verlust je Aktie $0.20) und einen Sechsmonatsverlust von $1,903,941.
Die Liquidit盲tslage 盲nderte sich deutlich: Zahlungsmittel und Zahlungsmittel盲quivalente stiegen von $437,604 zum Jahresende auf $2,275,344, haupts盲chlich durch die Aus眉bung von Warrants, die Bruttoerl枚se von etwa $3.8 Mio. und $3,493,505 an Nettofinanzierungszufluss erzeugten. Das Working Capital betrug etwa $503,000. Das Management 盲u脽ert erhebliche Zweifel an der Fortf眉hrungsf盲higkeit des Unternehmens ohne zus盲tzliche Finanzierung. Eine hohe Kundenkonzentration bleibt bestehen (zwei Kunden machten 47% des Quartalsumsatzes aus) und das Inventar enth盲lt eine gro脽e R眉ckstellung f眉r fertige Erzeugnisse im Zusammenhang mit verz枚gerten Projekten.
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
or
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period from to
Commission file number
BIO-KEY INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
| | |
| (State or Other Jurisdiction of Incorporation of Organization) | (IRS Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuance to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| | | |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ |
| Accelerated filer ☐ |
| |
| Smaller Reporting Company |
|
| Emerging growth company | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act) Yes
Number of shares of Common Stock, $.0001 par value per share, outstanding as of August 12, 2025, is
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
INDEX
| PART I. FINANCIAL INFORMATION |
3 |
| Item 1— Financial Statements: |
|
| Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 |
3 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) |
4 |
| Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024 (Unaudited) |
5 |
| Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) |
7 |
| Notes to Condensed Consolidated Financial Statements |
9 |
| Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
16 |
| Item 3—Quantitative and Qualitative Disclosures about Market Risk. | 23 |
| Item 4—Controls and Procedures. |
23 |
| PART II. OTHER INFORMATION |
24 |
| Item 1—Legal Proceedings. | 24 |
| Item 1A—Risk Factors. | 24 |
| Item 2—Unregistered Sales of Equity Securities and Use of Proceeds. | 24 |
| Item 3—Defaults upon Senior Securities. | 24 |
| Item 4—Mine Safety Disclosures. | 24 |
| Item 5—Other Information. | 24 |
| Item 6—Exhibits. |
24 |
| Signatures |
25 |
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Due from factor | ||||||||
| Inventory | ||||||||
| Prepaid expenses and other | ||||||||
| Total current assets | ||||||||
| Equipment and leasehold improvements, net | ||||||||
| Capitalized contract costs, net | ||||||||
| Deposits and other assets | ||||||||
| Operating lease right-of-use assets | ||||||||
| Investments | ||||||||
| Intangible assets, net | ||||||||
| Total non-current assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Note payable | ||||||||
| Government loan – BBVA Bank, current portion | ||||||||
| Deferred revenue, current | ||||||||
| Operating lease liabilities, current portion | ||||||||
| Total current liabilities | ||||||||
| Deferred revenue, long term | ||||||||
| Government loan – BBVA Bank – net of current portion | ||||||||
| Operating lease liabilities, net of current portion | ||||||||
| Total non-current liabilities | ||||||||
| TOTAL LIABILITIES | ||||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 6,848,776 and 3,715,483 of $.0001 par value at June 30, 2025 and December 31, 2024, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive income | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| Three Months Ended |
Six Months Ended |
|||||||||||||||
| June 30, |
June 30, |
|||||||||||||||
| 2025 |
2024 |
2025 |
2024 |
|||||||||||||
| Revenues |
||||||||||||||||
| Services |
$ | $ | $ | $ | ||||||||||||
| License fees |
||||||||||||||||
| Hardware |
||||||||||||||||
| Total revenues |
||||||||||||||||
| Costs and other expenses |
||||||||||||||||
| Cost of services |
||||||||||||||||
| Cost of license fees |
||||||||||||||||
| Cost of hardware |
||||||||||||||||
| Cost of hardware - reserve |
( |
) | ( |
) | ||||||||||||
| Total costs and other expenses |
||||||||||||||||
| Gross profit |
||||||||||||||||
| Operating expenses |
||||||||||||||||
| Selling, general and administrative |
||||||||||||||||
| Research, development and engineering |
||||||||||||||||
| Total operating expenses |
||||||||||||||||
| Operating loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Other income (expense) |
||||||||||||||||
| Interest income |
||||||||||||||||
| Loan fee amortization |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Change in fair value of convertible note |
||||||||||||||||
| Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Total other income (expense), net |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Loss before provision for income tax |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Provision for (income tax) tax benefit |
||||||||||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Comprehensive loss: |
||||||||||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Other comprehensive income (loss) – foreign currency translation adjustment |
( |
) | ||||||||||||||
| Comprehensive loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Basic and diluted loss per common share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
| Weighted average common shares outstanding: |
||||||||||||||||
| Basic and diluted |
||||||||||||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| Accumulated |
||||||||||||||||||||||||
| Additional |
Other |
|||||||||||||||||||||||
| Common Stock |
Paid-in |
Comprehensive |
Accumulated |
|||||||||||||||||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Total | |||||||||||||||||||
| Balance as of January 1, 2025 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
| Issuance of common stock for directors’ fees |
- | |||||||||||||||||||||||
| Issuance of restricted stock to employees |
||||||||||||||||||||||||
| Issuance of common stock for repayment of debt |
||||||||||||||||||||||||
| Restricted stock forfeited |
( |
) | - | - | - | - | - | |||||||||||||||||
| Exercise of warrants |
||||||||||||||||||||||||
| Foreign currency translation adjustment |
- | |||||||||||||||||||||||
| Share-based compensation |
- | |||||||||||||||||||||||
| Issuance costs |
- | ( |
) | ( |
) | |||||||||||||||||||
| Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
| Balance as of March 31, 2025 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
| Issuance of common stock for directors’ fees |
||||||||||||||||||||||||
| Issuance of common stock for repayment of debt |
||||||||||||||||||||||||
| Restricted stock forfeited |
( |
) | ( |
) | ||||||||||||||||||||
| Issuance of restricted common stock to employees and directors |
( |
) | ||||||||||||||||||||||
| Share-based compensation for Employee Stock Purchase Plan |
- | |||||||||||||||||||||||
| Issuance of common stock for Employee Stock Purchase Plan | - | - | - | - | - | |||||||||||||||||||
| Foreign currency translation adjustment |
- | |||||||||||||||||||||||
| Share-based compensation |
- | |||||||||||||||||||||||
| Exercise of warrants |
( |
) | ||||||||||||||||||||||
| Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
| Balance as of June 30, 2025 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| Accumulated |
||||||||||||||||||||||||
| Additional |
Other |
|||||||||||||||||||||||
| Common Stock |
Paid-in |
Comprehensive |
Accumulated |
|||||||||||||||||||||
| Shares |
Amount |
Capital |
Income (Loss) |
Deficit |
Total |
|||||||||||||||||||
| Balance as of January 1, 2024 |
$ | $ | $ | $ | ( |
) | $ | |||||||||||||||||
| Issuance of common stock for directors’ fees |
||||||||||||||||||||||||
| Restricted stock forfeited |
( |
) | - | - | - | - | - | |||||||||||||||||
| Exercise of warrants |
||||||||||||||||||||||||
| Foreign currency translation adjustment |
- | ( |
) | ( |
) | |||||||||||||||||||
| Share-based compensation |
- | |||||||||||||||||||||||
| Issuance costs |
- | ( |
) | ( |
) | |||||||||||||||||||
| Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
| Balance as of March 31, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
| Restricted stock forfeited |
( |
) | ||||||||||||||||||||||
| Issuance of common stock for Employee Stock Purchase Plan |
||||||||||||||||||||||||
| Share-based compensation for Employee Stock Purchase Plan |
- | |||||||||||||||||||||||
| Foreign currency translation adjustment |
- | |||||||||||||||||||||||
| Share-based compensation |
- | |||||||||||||||||||||||
| Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
| Balance as of June 30, 2024 |
$ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Six Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| CASH FLOW FROM OPERATING ACTIVITIES: |
||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | ||
| Adjustments to reconcile net loss to net cash used for operating activities: |
||||||||
| Depreciation |
||||||||
| Amortization of intangible assets |
||||||||
| Amortization of capitalized contract costs |
||||||||
| Amortization of note payable |
||||||||
| Interest payable on note |
||||||||
| Operating leases right-of-use assets |
||||||||
| Share and warrant-based compensation for employees and consultants |
||||||||
| Share-based directors’ fees |
||||||||
| Bad debts |
||||||||
| Change in assets and liabilities: |
||||||||
| Accounts receivable |
( |
) | ||||||
| Allowance for doubtful receivables |
( |
) | ||||||
| Due from factor |
( |
) | ||||||
| Capitalized contract costs |
( |
) | ( |
) | ||||
| Inventory |
||||||||
| Prepaid expenses and other |
( |
) | ( |
) | ||||
| Accounts payable |
||||||||
| Accrued liabilities |
( |
) | ( |
) | ||||
| Deferred revenue |
||||||||
| Operating lease liabilities |
( |
) | ( |
) | ||||
| Net cash used in operating activities |
( |
) | ( |
) | ||||
| CASH FLOW FROM INVESTING ACTIVITIES: |
||||||||
| Capital expenditures |
( |
) | ( |
) | ||||
| Net cash used in investing activities |
( |
) | ( |
) | ||||
| CASH FLOW FROM FINANCING ACTIVITIES: |
||||||||
| Proceeds from note payable |
||||||||
| Offering costs |
( |
) | ( |
) | ||||
| Proceeds for exercise of warrants |
||||||||
| Receipt of cash from employee stock purchase plan |
||||||||
| Repayment of government loan |
( |
) | ( |
) | ||||
| Net cash provided in financing activities |
||||||||
| Effect of exchange rate changes |
( |
) | ||||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
||||||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
||||||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD |
$ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION
| Six Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| Cash paid for: |
||||||||
| Interest |
$ | $ | ||||||
| Non-cash investing and financing activities |
||||||||
| Issuance of stock for repayment of debt |
$ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2025 (Unaudited)
| 1. | NATURE OF BUSINESS AND BASIS OF PRESENTATION |
Nature of Business
BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”), founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.
Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key and are stated in conformity with accounting principles generally accepted in the United States of America (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.
In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at June 30, 2025 was derived from the audited financial statements, but does not include all of the disclosures required by GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on June 5, 2024.
Foreign Currencies
The Company accounts for foreign currency transactions pursuant to Accounting Standards Codification ("ASC") 830, Foreign Currency Matters (“ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive income (loss).
Recently Issued Accounting Pronouncements
In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 was effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis. The adoption of ASU 2020-06 did not have a material effect on the consolidated financial statements of the Company.
Management does not believe that any other recently issued, but not yet effective, accounting standard, if currently adopted, would have a material effect on the accompanying consolidated financial statements.
| 2. |
GOING CONCERN |
The Company has historically financed operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and is, therefore looking into other markets and opportunities to sell or return the product to generate additional cash.
The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations, all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.
| 3. |
REVENUE FROM CONTRACTS WITH CUSTOMERS |
Disaggregation of Revenue
The following table summarizes revenue from contracts with customers for the three-month periods ended June 30, 2025 and June 30, 2024:
| North |
June 30, |
|||||||||||||||||||
| America |
Africa |
EMESA* |
Asia |
2025 |
||||||||||||||||
| Services |
$ | $ | $ | $ | $ | |||||||||||||||
| License fees |
||||||||||||||||||||
| Hardware |
||||||||||||||||||||
| Total revenues |
$ | $ | $ | $ | $ | |||||||||||||||
| North |
June 30, |
|||||||||||||||||||
| America |
Africa |
EMESA* |
Asia |
2024 |
||||||||||||||||
| Services |
$ | $ | $ | $ | $ | |||||||||||||||
| License fees |
||||||||||||||||||||
| Hardware |
||||||||||||||||||||
| Total revenues |
$ | $ | $ | $ | $ | |||||||||||||||
The following table summarizes revenue from contracts with customers for the six-month periods ended June 30, 2025 and June 30, 2024:
| North |
June 30, |
|||||||||||||||||||
| America |
Africa |
EMESA* |
Asia |
2025 |
||||||||||||||||
| Services |
$ | $ | $ | $ | $ | |||||||||||||||
| License fees |
||||||||||||||||||||
| Hardware |
||||||||||||||||||||
| Total revenues |
$ | $ | $ | $ | $ | |||||||||||||||
| North |
June 30, |
|||||||||||||||||||
| America |
Africa |
EMESA* |
Asia |
2024 |
||||||||||||||||
| Services |
$ | $ | $ | $ | $ | |||||||||||||||
| License fees |
||||||||||||||||||||
| Hardware |
||||||||||||||||||||
| Total revenues |
$ | $ | $ | $ | $ | |||||||||||||||
*EMESA – Europe, Middle East, South America
Deferred Revenue
Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is
| 4. |
ACCOUNTS RECEIVABLE |
Accounts receivable are carried at original amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.
Accounts receivable at June 30, 2025 and December 31, 2024 consisted of the following:
| June 30, |
December 31, |
|||||||
| 2025 |
2024 |
|||||||
| Accounts receivable |
$ | 1,366,787 | $ | |||||
| Allowance for credit losses |
( |
) | ( |
) | ||||
| Accounts receivable, net of allowances for credit losses |
$ | $ | ||||||
Bad debt expenses are recorded in selling, general, and administrative expense.
| 5. |
SHARE-BASED COMPENSATION |
The following table presents share-based compensation expenses included in the Company’s unaudited condensed interim consolidated statements of operations:
| Three Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| Selling, general and administrative |
$ | $ | ||||||
| Research, development and engineering |
||||||||
| $ | $ | |||||||
| Six Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| Selling, general and administrative |
$ | $ | ||||||
| Research, development and engineering |
||||||||
| $ | $ | |||||||
| 6. |
INVENTORY |
Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The reserve on inventory is due to slow moving inventory purchased for projects in Nigeria, and slow-moving inventory. The Company has been selling units in small quantities and continues to explore other markets and opportunities to sell the product. Inventory is comprised of the following as at June 30, 2025 and December 31, 2024:
| June 30, |
December 31, |
|||||||
| 2025 |
2024 |
|||||||
| Finished goods |
$ | $ | ||||||
| Fabricated assemblies |
||||||||
| Reserve on finished goods |
( |
) | ( |
) | ||||
| Total inventory |
$ | $ | ||||||
7. INVESTMENTS
Equity Investment in Privately Held Company
On November 27, 2024, the Company purchased
The purchase agreement between the Company and Fiber Food contemplates collaboration between the parties regarding potential strategic and commercial transactions, including acquiring assets or equity interests in other operating companies, integrating the Company’s identity access management solutions into Fiber Food’s offerings, and introducing the Company to its customers, affiliates and business contacts who are potential users of the Company’s solutions, in each case pursuant to future definitive agreements on terms to be negotiated by the parties. The Company has engaged in discussions with Fiber Food and Boumarang, Inc. regarding the contemplated collaboration, but no definitive agreements have been executed. In the event that at any time during the nine-month period after the closing of the transaction the Company values the Boumarang Shares at less than $
The Boumarang Shares constitute an investment in a privately held company for which there is no trading market and are carried at fair value. Fair value is the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use in pricing the asset or liability, such as inherent risk, non-performance risk and credit risk. The Company follows ASC 820 – “Fair Value Measurement,” which establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy categorizes assets and liabilities measured at fair value into one of three different levels depending on the observability of the inputs employed in the measurement. The three levels are defined as follows:
Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived from observable market data by correlation or other means.
Level 3: Inputs for the asset or liability that are not based on observable market data (unobservable inputs).
The Boumarang Shares are classified as a Level 3 asset and have been valued based on a combination of recent sales of Boumarang common stock to third parties and a third party valuation applying a discounted cash flow analysis which included discounts for lack of control and lack of marketability, small company risk premium, and specific company risk premium based on Boumarang being an early-stage pre-revenue company. The lack of control and marketability discounts were based on published studies and transfer restrictions contained in Boumarang, Inc’s corporate governance documents.
Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Boumarang Shares may fluctuate from period to period and the fair value of the Boumarang Shares may differ significantly from the values that would have been used had a ready market existed for such shares and may differ materially from the values that the Company may ultimately realize. The early-stage pre-revenue status and unproven technology of Boumarang, Inc. raise uncertainties that could impact the recoverability of the investment in the Boumarang Shares.
ASC 321-10-35 Equity Securities - Subsequent Measurement requires annual impairment testing for equity securities without readily determinable fair values.
| 8. |
COMMITMENTS AND CONTINGENCIES |
Litigation
From time to time, the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of June 30, 2025, the Company was not a party to any pending lawsuits.
| 9. |
LEASES |
The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2027. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:
| 3 Months ended |
3 Months ended |
|||||||
| June 30, |
June 30, |
|||||||
| 2025 |
2024 |
|||||||
| Lease cost |
||||||||
| Total lease cost |
$ | $ | ||||||
| 6 Months ended |
6 Months ended |
|||||||
| June 30, |
June 30, |
|||||||
| 2025 |
2024 |
|||||||
| Lease cost |
||||||||
| Total lease cost |
$ | $ | ||||||
| June 30, |
December 31, |
|||||||
| Balance sheet information |
2025 |
2024 |
||||||
| Operating right-of-use assets |
$ | $ | ||||||
| Operating lease liabilities, current portion |
$ | $ | ||||||
| Operating lease liabilities, non-current portion |
||||||||
| Total operating lease liabilities |
$ | $ | ||||||
| Weighted average remaining lease term (in years) – operating leases |
||||||||
| Weighted average discount rate – operating leases |
% | % | ||||||
| Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June 30, 2025 and 2024: |
$ | $ | ||||||
Maturities of operating lease liabilities were as follows as of June 30, 2025:
| 2025 (6 months remaining) |
$ | |||
| 2026 |
||||
| 2027 |
||||
| 2028 |
||||
| Total future lease payments |
$ | |||
| Less: imputed interest |
( |
) | ||
| Total |
$ |
| 10. |
NOTE PAYABLE |
Note Purchase Agreement dated June 24, 2024
On June 24, 2024, the Company entered into and closed a note purchase agreement (the “Purchase Agreement”) which provided for the issuance of a $
The principal amount of the 2024 Note is due 18 months following the date of issuance. Interest under the 2024 Note accrues at a rate of nine percent (
The 2024 Note is secured by a lien on substantially all of the Company’s assets and properties and the Company’s obligations under the 2024 Note are guaranteed by Pistol Star, Inc., a wholly owned subsidiary of the Company. The 2024 Note can be prepaid in whole or in part without penalty at any time. In the event that the Company receives any proceeds in connection with any fundraising or financing transaction (including any warrant exercises), it will be required to make a mandatory prepayment equal to the lesser of (i) forty percent (
The 2024 Note provides for customary events of default, including, among other things, the event of non-payment of principal, interest, fees or other amounts, a representation or warranty proving to have been incorrect when made, failure to perform or observe covenants within a specified period of time, the bankruptcy or insolvency of the Company or of all or a substantial part of its property, and monetary judgment defaults of a specified amount. Upon the occurrence of an Event of Default, Lender may (i) cause interest on the outstanding balance to accrue at an interest rate equal to the lesser of twenty two (
In the third quarter of 2024, the Company received gross proceeds of approximately $
In January 2025, the Company entered into two Exchange Agreements with the holder of the 2024Note pursuant to which it partition from the 2024 Note two new promissory notes in the original principal amounts of $
| 11. |
EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”) |
The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.
Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares, and they were also excluded from diluted earnings per share due to anti-dilution:
| Three Months ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Stock options | ||||||||||||||||
| Warrants | ||||||||||||||||
| Total | ||||||||||||||||
| 12. | STOCKHOLDERS’ EQUITY |
Issuances of Common Stock
During the six-month periods ended June 30, 2025, and 2024, there have not been any shares of common stock issued to anyone outside the Company, except as noted in this Note 12.
On June 18, 2021, the stockholders approved the Employee Stock Purchase Plan. Under the terms of this plan,
Issuances of Restricted Stock
Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Nonvested stock is expensed ratably over the term of the restriction period.
During the six-month periods ended June 30, 2025 and 2024, the Company issued
During the six-month periods ended June 30, 2025 and 2024,
Share based compensation for the six-month periods ended June 30, 2025 and 2024, was $
Issuances to Directors
During the six-month periods ended June 30, 2025, and 2024, the Company issued
Employees’ exercise options
During the six-month periods ended June 30, 2025 and 2024, no employee stock options were exercised.
3. Warrants
On January 15, 2025, the Company entered into a warrant exercise agreement (the "Warrant Exercise Agreement") with an existing institutional investor (the "Investor") to exercise certain outstanding warrants to purchase an aggregate of
There were
4. Partitioned Notes
During the three-month period ended June 30, 2025, partitioned notes in the aggregate principal amount of $
| 13. |
FAIR VALUES OF FINANCIAL INSTRUMENTS |
Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s government loan payable approximates fair value as the interest rate related to the financial instruments approximated market.
| 14. | MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE |
During each of the three-month periods ended June 30, 2025, and 2024, two customers accounted for
Two customers accounted for
| 15. | INCOME TAXES |
United States, Hong Kong and Nigeria
The Company recorded
As of June 30, 2025 and December 31, 2024, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
Spain
Due to the current loss for the six months ended June 30, 2025, the Company did not record income taxes.
| 16 | SUBSEQUENT EVENTS |
On August 7, 2025, the Company issued an aggregate of
The Company has reviewed subsequent events through the date of this filing.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and Portal Guard offerings; our ability to execute definitive agreements with Fiber Food Systems and/or its customers to utilize our access management solutions; our ability to integrate our solutions into any of Fiber Food System’s offerings; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of the restatement of our financial statements including any consequences of non-compliance with the Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to maintain effective controls over financial reporting, statements of assumption underlying any of the foregoing, and numerous other matters of national, regional and global scale, including those set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is provided as a supplement to and should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and our audited financial statements as of December 31, 2024.
Overview
BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity access management, or IAM, platform provider for the enterprise and large-scale customer and civil ID solutions. Built to leverage BIO-key’s world-class biometric core platform among seventeen strong authentication factors, BIO-key PortalGuard and hosted PortalGuard IDaaS platforms that enable our customers to securely and easily assure that only the right people can access the right systems. PortalGuard goes beyond traditional multifactor authentication (MFA) solutions by addressing functional gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification.
Our customers use BIO-key every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. Employees, contractors, students and faculty sign in through PortalGuard to seamlessly and securely access the applications they need to do their important work, without relying on personal phone use or per-user tokens. Organizations use our platform to securely collaborate with their supply chain and partners, and to provide their customers with flexible, resilient user experiences online or in-person.
Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. One large bank has enrolled and identifies over 21.7 million of their customers using BIO-key fingerprint biometrics in branches on a daily basis.
PortalGuard and Identity-Bound Biometrics, or IBB, deliver unique value to enterprises who find that mainstream MFA solutions do not adequately address their workforce use cases. PortalGuard operates as a single MFA user experience, providing a wide set of authentication choices to meet every use case. We sell our branded biometric and Fast Identity Online, or FIDO, authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. We do not mandate the use of BIO-key hardware with our software and services. Our National Institute of Standards, and Technology, or NIST, certified fingerprint biometric platform is unique in that it supports interoperable mixing and matching combinations of different manufactures’ fingerprint scanners in a deployment, so that the right scanner can be selected for the right use case, without mandating the use of a particular scanner.
Security-conscious software developers leverage our platform APIs and federation interfaces to securely and efficiently embed biometric and MFA identity capabilities into their software. Our approach to IDaaS allows our customers to efficiently scale their security and identity infrastructures to protect both internal cloud workforce- and external customer-facing applications.
In 2022, we expanded our product offerings and customer base when we acquired Swivel Secure, a Madrid, Spain based provider of IAM solutions. Until the fourth quarter of 2024, Swivel Secure was the exclusive distributer of AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland. Swivel Secure, now operates as BIO-key EMEA maintains a direct sales force with offices in Madrid, Spain and Lisbon, Portugal, and sells only BIO-key products.
We operate a software as a service, or SaaS, business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year.
Strategic Outlook
We plan to have a more significant role in the IAM market which continues to expand. We plan to continue to offer customers a suite of authentication options that complement our biometric solutions. The more well-rounded offerings of authentication options will allow customers to customize their approach to authentication all under one umbrella.
We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare. We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 10 users will accelerate the demand for our computer network log-on solutions and fingerprint readers. Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base.
Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than eighty-five participants and continues to generate incremental revenues.
A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space. In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings. We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations.
Recent Developments
The current trend of continued remote work environments increases the risk of unauthorized users, phishing attacks, and hackers who are eager to take advantage of the challenges of securing remote workers. A growing trend of security incidents that highlight potential cybersecurity vulnerabilities, additional regulatory requirements, and increasingly stringent Cyber Insurance underwriting standards that mandate enhanced security solutions has resulted in many businesses requiring MFA for their employees, partners and customers to access their business systems and data. We believe that biometrics should continue to play a key role in remote user authentication.
Critical Accounting Policies and Estimates
For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K.
Recent Accounting Pronouncements
For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
RESULTS OF OPERATIONS
THREE MONTHS ENDED June 30, 2025 AS COMPARED TO June 30, 2024
Consolidated Results of Operations - Percent Trend
| Three Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| Revenues |
||||||||
| Services |
19 | % | 25 | % | ||||
| License fees |
47 | % | 68 | % | ||||
| Hardware |
34 | % | 7 | % | ||||
| Total revenues |
100 | % | 100 | % | ||||
| Costs and other expenses |
||||||||
| Cost of services |
7 | % | 6 | % | ||||
| Cost of license fees |
5 | % | 13 | % | ||||
| Cost of hardware |
31 | % | 4 | % | ||||
| Cost of hardware - reserve |
-16 | % | 0 | % | ||||
| Total Cost and other expenses |
27 | % | 23 | % | ||||
| Gross profit |
73 | % | 77 | % | ||||
| Operating expenses |
||||||||
| Selling, general and administrative |
99 | % | 170 | % | ||||
| Research, development and engineering |
38 | % | 52 | % | ||||
| Total Operating Expenses |
137 | % | 222 | % | ||||
| Operating loss |
-64 | % | -145 | % | ||||
| Other expense |
-5 | % | -1 | % | ||||
| Loss before provision for income tax |
-69 | % | -146 | % | ||||
| Provision for income tax |
0 | % | 0 | % | ||||
| Net loss |
-69 | % | -146 | % | ||||
Revenues and cost of goods sold
| Three Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Revenues |
||||||||||||||||
| Service |
$ | 321,996 | $ | 283,569 | $ | 38,427 | 14 | % | ||||||||
| License |
806,087 | 774,225 | 31,862 | 4 | % | |||||||||||
| Hardware |
568,824 | 83,492 | 485,332 | 581 | % | |||||||||||
| Total Revenue |
$ | 1,696,907 | $ | 1,141,286 | $ | 555,621 | 49 | % | ||||||||
| Three Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Costs and other expenses |
||||||||||||||||
| Service |
$ | 118,301 | $ | 73,385 | $ | 44,916 | 61 | % | ||||||||
| License |
86,488 | 148,432 | (61,944 | ) | -42 | % | ||||||||||
| Hardware |
536,806 | 40,455 | 496,351 | 1227 | % | |||||||||||
| Hardware - reserve |
(277,415 | ) | - | (277,415 | ) | 100 | % | |||||||||
| Total Costs and other expenses |
$ | 464,180 | $ | 262,272 | $ | 201,908 | 77 | % | ||||||||
Revenues
For the three months ended June 30, 2025, and 2024, service revenues included approximately $271,000 and $274,000, respectively, of recurring maintenance and support revenue, and approximately $51,000 and $10,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased $3,000 or 1% in 2025 which was due to the timing of renewals of service agreements. Non-recurring custom services increased 412% due to an upgrade for one large customer. Overall, service revenues increased 14% to $321,996 from $283,569 in the corresponding period in 2024.
For the three months ended June 30, 2025, license revenue increased $31,862 or 4% to $806,087 from $774,225 in the corresponding period in 2024 , due to the ramp up of BIO-key EMEA selling only BIO-key products which we expect to accelerate in 2025.
For the three months ended June 30, 2025, hardware sales increased 581% to $568,824 from $83,492 in the corresponding period in 2024. The increase was due largely to one long-term customer expanding its purchase of biometric cybersecurity solutions.
Costs and other expenses
For the three months ended June 30, 2025, cost of service increased $44,916 or 61% to $118,301 from $73,385 in the three months ended June 30, 2024, due to an upgrade for one large customer. For the three months ended June 30, 2025, license fees decreased to $86,488 from $148,432 in the three months ended June 30, 2024, due to the absence of license fees for third-party software included in our previous Swivel Secure product offerings. For the three months ended June 30, 2025, hardware costs increased to net cost of $258,391 (after giving effect to the $277,415 reversal of the reserve for inventory) from $40,455 in the three months ended June 30, 2024, related to increased hardware revenue which included sales of a portion of our fully reserved inventory.
Selling, general and administrative
| Three Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 1,680,550 | $ | 1,941,866 | $ | (261,316 | ) | -13 | % | |||||||
Selling, general and administrative expenses for the three months ended June 30, 2025, decreased 13% from $1,941,866 in the corresponding period in 2024 to $1,680,550 in the current quarter. The decreases included reductions in administration, sales personnel costs, and professional services fees.
Research, development and engineering
| Three Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Research, development, and engineering |
$ | 636,027 | $ | 591,234 | $ | 44,793 | 8 | % | ||||||||
For the three months ended June 30, 2025, research, development, and engineering costs increased 8% to $636,027 compared to $591,234 in the corresponding period in 2024. The increase consisted primarily of professional services and personnel costs, offset by a decrease in rent costs.
Other income (expense)
| Three Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Interest income |
$ | 2,092 | $ | 46 | $ | 2,046 | 4448 | % | ||||||||
| Loan fee amortization |
(60,000 | ) | (4,000 | ) | (56,000 | ) | -93 | % | ||||||||
| Interest expense |
(25,638 | ) | (8,910 | ) | (16,728 | ) | -188 | % | ||||||||
| Other income (expense) |
$ | (83,546 | ) | $ | (12,864 | ) | $ | (70,682 | ) | -549 | % | |||||
Other income (expense) for the three months ended June 30, 2025 consisted of interest income of $2,092, interest expense of $25,638 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $60,000. Other income (expense) for the three months ended June 30, 2024 consisted of interest income of $46 and interest expense of $8,910 comprised of approximately $1,400 on the government loan through the BBVA bank and the balance on the 2024 Note, and a loan fee amortization amount of $4,000.
Six MONTHS ENDED June 30, 2025 AS COMPARED TO June 30, 2024
Consolidated Results of Operations - Percent Trend
| Six Months Ended June 30, |
||||||||
| 2025 |
2024 |
|||||||
| Revenues |
||||||||
| Services |
18 | % | 15 | % | ||||
| License fees |
58 | % | 82 | % | ||||
| Hardware |
24 | % | 3 | % | ||||
| Total Revenues |
100 | % | 100 | % | ||||
| Costs and other expenses |
||||||||
| Cost of services |
6 | % | 6 | % | ||||
| Cost of license fees |
5 | % | 9 | % | ||||
| Cost of hardware |
19 | % | 2 | % | ||||
| Cost of hardware - reserve |
-8 | % | 0 | % | ||||
| Total Cost of Goods Sold |
22 | % | 17 | % | ||||
| Gross profit |
78 | % | 83 | % | ||||
| Operating expenses |
||||||||
| Selling, general and administrative |
93 | % | 112 | % | ||||
| Research, development and engineering |
37 | % | 36 | % | ||||
| Total Operating Expenses |
130 | % | 148 | % | ||||
| Operating loss |
-52 | % | -65 | % | ||||
| Other expense |
-6 | % | -1 | % | ||||
| Loss before provision for income tax |
-58 | % | -66 | % | ||||
| Provision for income tax |
0 | % | 0 | % | ||||
| Net loss |
-58 | % | -66 | % | ||||
Revenues and cost of goods sold
| Six Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Revenues |
||||||||||||||||
| Service |
$ | 594,594 | $ | 496,690 | $ | 97,904 | 20 | % | ||||||||
| License |
1,904,845 | 2,724,659 | (819,814 | ) | -30 | % | ||||||||||
| Hardware |
804,627 | 101,140 | 703,487 | 696 | % | |||||||||||
| Total Revenue |
$ | 3,304,066 | $ | 3,322,489 | $ | (18,423 | ) | -1 | % | |||||||
| Cost of Goods Sold |
||||||||||||||||
| Service |
216,445 | 212,234 | 4,211 | 2 | % | |||||||||||
| License |
159,373 | 296,652 | (137,279 | ) | -46 | % | ||||||||||
| Hardware |
645,275 | 53,029 | 592,246 | 1117 | % | |||||||||||
| Hardware - reserve |
(277,415 | ) | - | (277,415 | ) | -100 | % | |||||||||
| Total COGS |
$ | 743,678 | $ | 561,915 | $ | 181,763 | 32 | % | ||||||||
Revenues
For the six months ended June 30, 2025, and 2024, service revenues included approximately $535,000 and $467,000, respectively, of recurring maintenance and support revenue, and approximately $59,000 and $30,000 respectively, of non-recurring custom services revenue. Recurring service revenue increased $68,000 or 15% in 2025 which was due to the updated support for a large customer service agreement. Non-recurring custom services increased 100% due to an upgrade for one large customer. Overall, service revenues increased 20% to $594,594 $496,690 in the corresponding period in 2024.
For the six months ended June 30, 2025, license revenue decreased $819,814 or 30% to $1,904,845 from $2,724,659 in the corresponding period in 2024, due to the ramp up of BIO-key EMEA selling only BIO-key product which we expect to accelerate in 2025.
Costs of goods sold
For the six months ended June 30, 2025, cost of service increased $4,211 or 2% to $216,445 from $212,234 in the six months ended June 30, 2024, due to the costs associated with the upgrade for one large customer. For the six months ended June 30, 2025, license fees decreased to $159,373 from $296,652 in the six months ended June 30, 2024, due to the absence of license fees for third-party software included in our previous Swivel Secure product offerings. For the six months ended June 30, 2025, hardware costs increased to a net cost of $314,831 (after giving effect to the $277,415 reversal of the reserve for inventory) from $53,0293 in the six months ended June 30, 2024, related to increased hardware revenue which included sales of a portion of our fully reserved inventory.
Selling, general and administrative
| Six Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 3,053,074 | $ | 3,724,839 | $ | (671,765 | ) | -18 | % | |||||||
Selling, general and administrative expenses for the six months ended June 30, 2025, decreased 18% from $3,724,839 in the corresponding period in 2024 to $3,053,074 in the current quarter. The decreases included reductions in administration, sales personnel costs, and professional services fees.
Research, development and engineering
| Six Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Research, development and engineering |
$ | 1,231,802 | $ | 1,198,755 | $ | 33,047 | 3 | % | ||||||||
For the six months ended June 30, 2025, research, development, and engineering costs increased 3% to $1,231,802 compared to $1,198,755 in the corresponding period in 2024. The increase consisted primarily of professional services and personnel costs, offset by a decrease in rent costs.
Other income (expense)
| Six Months Ended |
||||||||||||||||
| June 30, |
||||||||||||||||
| 2025 |
2024 |
$ Change |
% Change |
|||||||||||||
| Interest income |
$ | 2,095 | $ | 51 | $ | 2,044 | 4008 | % | ||||||||
| Loan fee amortization |
(120,000 | ) | (4,000 | ) | (116,000 | ) | -103 | % | ||||||||
| Interest expense |
(61,548 | ) | (10,267 | ) | (51,281 | ) | -499 | |||||||||
| Other income (expense) |
$ | (179,453 | ) | $ | (14,216 | ) | $ | (165,237 | ) | -1162 | % | |||||
Other income (expense) for the six months ended June 30, 2025 consisted of interest income of $2,095, interest expense of $61,548 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $60,000. Other income (expense) for the six months ended June 30, 2024 consisted of interest income of $51 and interest expense of $10,267 consisting of approximately $2,700 on the government loan through the BBVA bank and the balance for interest accrued on the 2024 Note, as defined below, and a loan fee amortization amount of $4,000.
LIQUIDITY AND CAPITAL RESOURCES
Cash Flows
Operating activities overview
| Net cash used in operations during the six months ended June 30, 2025 was $1,715,324. Items of note included: |
| ● |
Net positive cash flows related to adjustments for non-cash expenses of approximately $592,000. |
| ● |
Net positive cash flows related to inventory, accounts payable, and deferred revenue of approximately $132,000. |
| ● |
Negative cash flows related to changes in accounts receivable and allowance, amount due from factor accounts, prepaid expenses, and accrued liabilities of approximately $535,000, due to working capital management. |
Financing activities overview
Net cash provided by financing activities during the six months ended June 30, 2025 was $3,493,505 which included $3,813,057 of proceeds from the exercise of warrants, and $876 from the purchase of shares in the Employee Stock Purchase Plan, which was offset by repayment of $71,645 of the government loan through the BBVA bank and $248,783 for offering costs.
Investing activities overview
Net cash used in investing activities during the six months ended June 30, 2025 consisted of capital expenditures was $6,048 for capital expenditures.
Liquidity and Capital Resources
Since our inception, our capital needs have been met through proceeds from the sale of equity and debt securities, and revenue. We expect capital expenditures to be less than $100,000 during the next twelve months.
The following sets forth our investment sources of capital during the previous two years:
On January 15, 2025, we entered into a warrant exercise agreement with an existing investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of 2,061,112 shares of common stock, at an exercise price of $1.85 per share which were originally issued to the Investor on September 12, 2024 (the "Existing Warrants"). In consideration for the exercise of the Existing Warrants, subject to compliance with the beneficial ownership limitations included in the Existing Warrants, the Investor received new warrants to purchase up to an aggregate of 3,091,668 shares of Common Stock ("New Warrants"). The New Warrants have substantially the same terms, are immediately exercisable at an exercise price of $2.15 per share and will expire five years from the date of issuance. The gross proceeds to the Company were approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On September 12, 2024, we entered into a warrant exercise agreement with the Investor to exercise certain outstanding warrants to purchase an aggregate of 1,030,556 shares of common stock. The warrants were originally issued to the Investor on October 31, 2023 and had an original exercise price of $3.15 per share. In consideration for the immediate exercise of the warrants, we reduced the exercise price of the warrants to $1.85 per share and issued to the Investor unregistered Series A Warrants to purchase an aggregate of 1,030,556 shares of common stock and unregistered Series B Warrants to purchase an aggregate of 1,030,556 shares of common stock, each with an exercise price of $1.85 per share. The Series A and Series B warrants share substantially the same terms, are immediately exercisable and will expire five years from the date of issuance. The forgoing transaction resulted in gross proceeds of approximately $1.9 million prior to deducting placement agent fees and estimated offering expenses.
On June 24, 2024, we entered into and closed a note purchase agreement which provided for the issuance of a $2,360,000 principal amount senior secured promissory note (the "2024 Note"). This resulted in gross proceeds of approximately $1,826,000 after deducting placement agent fees, estimated offering expenses, and the original issue discount. The 2024 Note is due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance of, the lender shall have the right to redeem up to $270,000 of principal amount each month. In connection with the September 12, 2024 warrant exercise agreement described above, we prepaid approximately $762,600 of the amount due under the 2024 Note. As of the date of this report, the outstanding principal amount due under the 2024 Note is approximately $338,400. For a more complete description of the 2024 Note, please see Note 10 to Our Condensed Consolidated Financial Statements included in Part I Item 1 of this report.
We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2025 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us, with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.
Liquidity outlook
At June 30, 2025, our total cash and cash equivalents were $2,275,344, as compared to $437,604 at December 31, 2024. At June 30, 2025, we had working capital of approximately $503,000
As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $812,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. We also have approximately $3.1 million of inventory (currently reserved) purchased for projects in Nigeria. We continue to explore other markets and opportunities to sell the product to generate additional cash. If we are unable to generate sufficient revenue to fund current operations and execute our business plan, we will need to obtain additional third-party financing. Unless we generate sufficient positive cash flow from operations or liquidation of existing inventory, we expect that we will need to obtain additional financing during the next twelve months to support operations.
Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of this report, we are not a party to any pending lawsuits.
ITEM 1A. RISK FACTORS
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On May 30, 2025, we issued 259,403 shares of the Company’s Common Stock to one accredited investor in exchange for an outstanding promissory note in the principal amount of $200,000. The forgoing shares were issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 3(a)(9) under the Securities Act, without payment of placement agent fees or other remuneration to any person.
On June 9, 2025, we issued 239,034 shares of the Company’s Common Stock to one accredited investor in exchange for an outstanding promissory note in the principal amount of $200,000. The forgoing shares were issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 3(a)(9) under the Securities Act, without payment of placement agent fees or other remuneration to any person.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the three months ended June 30, 2025, none of our directors or “officers” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Securities and Exchange Commission Regulation S-K.
ITEM 6. EXHIBITS
| Exhibit No. |
Description |
|
| 31.1 |
Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended |
|
| 31.2 |
Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended |
|
| 32.1 |
Certificate of CEO of Registrant required under 18 U.S.C. Section 1350 |
|
| 32.2 |
Certificate of CFO of Registrant required under 18 U.S.C. Section 1350 |
|
| 101.INS |
Inline XBRL Instance |
|
| 101.SCH |
Inline XBRL Taxonomy Extension Schema |
|
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation |
|
| 101.DEF |
Inline XBRL Taxonomy Extension Definition |
|
| 101.LAB |
Inline XBRL Taxonomy Extension Labels |
|
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation |
|
| 104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIO-Key International, Inc. |
||
| Dated: August 13, 2025 |
/s/ Michael W. DePasquale |
|
| Michael W. DePasquale |
||
| Chief Executive Officer |
||
| (Principal Executive Officer) |
||
| Dated: August 13, 2025 |
/s/ Cecilia C. Welch |
|
| Cecilia C. Welch |
||
| Chief Financial Officer |
||
| (Principal Financial Officer) |
Source:
FAQ
What were BIO-key's (BKYI) total revenues for Q2 2025?
How much cash did BKYI report at June 30, 2025?
Did BIO-key disclose a going-concern issue in the 10-Q?
How did BKYI finance its cash increase in H1 2025?
What level of customer concentration does BKYI have?
What is the status of BIO-key's inventory reserves?
